USA Today reports:
Congressional ethics investigators have concluded there is “substantial reason to believe” Rep. Chris Collins, R-N.Y.. engaged in insider trading and either took or requested official actions to benefit a company in which he’s the largest shareholder, according to a report issued Thursday. Those may violations of House rules, standards of conduct and federal law, the report states.
Collins, R-N.Y., — who was the first member of Congress to endorse Donald Trump’s presidential campaign — is a board member of the Australian biotechnology company, Innate Immunotherapeutics. The report states Collins discussed Innate at a meeting at the National Institutes of Health in November 2013 and requested that an NIH employee meet with Innate employees to discuss clinical trial designs.